Opioid Use Disorder Clinical Trials
Opioid Use Disorder Clinical Trials
Phase 1
Phase 2
Phase 3
Phase 4
Opioid Use Disorder
Opioid Use Disorder
Opioid use treatment – CBOT Trial Are you or anyone you care about struggling with opioid usage? This might be a suitable trial for you.
Opioid Use Disorder
Phase 1
Phase 2
Phase 3
Phase 4
Opioid Use Disorder
Opioid use treatment – CBOT Trial Are you or anyone you care about struggling with opioid usage? This might be a suitable trial for you.
Frequently Asked Questions
What is the duration of the study?
This is a 6-month-long study with a few visits to one of our facilities at the beginning of
the study, a 3-month follow-up visit, and a 6-month follow-up visit.
What should I do during the study?
Participants will be using a new investigational at-home device that emits odors from
plant-based essential oils. This device was designed to help reduce opioid addiction.
What type of device is this?
It is a tabletop device that you can use in your home at a time that is convenient for you.
Will I be compensated for participating in the study?
Yes, study participation is voluntary and is compensated.
A clinical research study to evaluate and optimize the portable, home-based product, Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT), as an alternative strategy for relapse prevention in patients with Opioid Use (OUD) and other substance use disorders (SUD). The orbitofrontal cortex (OFC) plays important role in the regulation of addiction through the provision of an associative structure (i.e. cognitive map) for these mental simulations. Additionally, the OFC plays a critical role in emotion regulation through an enhanced cognitive reappraisal of negative affective cues; and negative affect is a strong predictor of substance relapse.
A clinical research study to evaluate and optimize the portable, home-based product, Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT), as an alternative strategy for relapse prevention in patients with Opioid Use (OUD) and other substance use disorders (SUD). The orbitofrontal cortex (OFC) plays important role in the regulation of addiction through the provision of an associative structure (i.e. cognitive map) for these mental simulations. Additionally, the OFC plays a critical role in emotion regulation through an enhanced cognitive reappraisal of negative affective cues; and negative affect is a strong predictor of substance relapse.
People with OUD have reduced OFC volume and function, and heroin and cocaine dose-dependently diminish OFC neuronal functions, thereby fueling recurrent drug use. The CBOT is a programmed, portable, safe, user-friendly device for conjoined chemosensory stimulation of OFC neural activity with stimulation parameters that overcome OFC desensitization, and for the administration of olfactory cognitive tasks that synergistically engage the OFC with high fidelity sufficient to induce lasting changes in OFC functions.
Interested to Participate in The Study?
Are you or anyone you care about struggling with opioid usage? This might be a suitable trial.
